Home › Urothelial (Transitional Cell) Carcinoma › Massachusetts › Worcester
Urothelial (Transitional Cell) Carcinoma clinical trials in Worcester, MA
4 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around Worcester (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
RecruitingPhase 3
- UMass Memorial Medical Center - University Campus, Worcester
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
- University of Massachusetts Medical School, Worcester
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RecruitingPhase 2
- UMass Memorial Medical Center, Worcester
- University of Massachusetts Chan Medical School, Worcester
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Worcester
Urothelial (Transitional Cell) Carcinoma trials in other cities
- Nashville, TN23 studies
- New York City, NY22 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Houston, TX18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Chicago, IL14 studies
- Arlington, VA12 studies
- San Antonio, TX11 studies
- Boston, MA11 studies
- Austin, TX10 studies
Other studies in Worcester
- Non-Small Cell Lung Cancer14 studies
- Lung Cancer11 studies
- Cancer (all types)7 studies
- Breast Cancer6 studies
- Schizophrenia5 studies
- Metastatic Cancer5 studies
- Prostate Cancer5 studies
- Ovarian Cancer5 studies
- Major Depressive Disorder5 studies
- Depression5 studies
- Acute Myeloid Leukemia5 studies
- Bladder Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.